Abstract P2040: Pannexin 1 Activation Drives Neutrophil Recruitment In A Murine Model Of Non-ischemic Heart Failure Induced By Isoproterenol
Caitlin M Pavelec,Nabin Poudel,Emily Orrell,Samantha Thomas,Hannah Luviano,Scott Yeudall,Clint Upchurch,Subramanian Senthivinayagam,Matthew J Wolf,Norbert Leitinger
DOI: https://doi.org/10.1161/res.133.suppl_1.p2040
IF: 23.213
2023-08-04
Circulation Research
Abstract:Pannexin 1 (Panx1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation and blood pressure regulation. Panx1 channel function is inhibited by spironolactone, a frontline therapy for heart failure patients. Despite this, the function of Panx1 in cardiomyocytes and a possible role in heart failure has not yet been studied. To investigate if Panx1 is involved in the development of non-ischemic heart failure, we use an acute (14 day) model of adrenergic stimulation (isoproterenol) to induce non-ischemic heart failure in a novel mouse model we have generated with constitutive deletion of Panx1 in cardiomyocytes by crossing mice expressing loxP-flanked alleles of Panx1 to mice expressing Cre recombinase under the control of the cardiomyocyte specific MyHC6 promoter (Panx1 MyHC6-Cre ). Constitutive deletion of Panx1 in cardiomyocytes had no effect on heart function at baseline, but protected mice against isoproterenol-induced non-ischemic heart failure (15 mg/kg/day isoproterenol, i.p.). Panx1 MyHC6-Cre mice were protected from systolic and diastolic dysfunction and cardiac hypertrophy as measured by echocardiography and heart mass, respectively. Moreover, Panx1 MyHC6-Cre mice demonstrated decreased recruitment of immune cells (CD45 + ), particularly neutrophils (CD11b + , Ly6g + ) to the myocardium as measured by confocal microscopy and flow cytometry. In vitro , treatment of H9c2 rat myoblasts with isoproterenol led to Panx1-dependent release of ATP and Yo-Pro-1 uptake in a dose-dependent manner, as assessed by pharmacological blockade by spironolactone and siRNA-mediated knock-down of Panx1. These data demonstrate that that β-adrenergic stimulation in cardiomyocytes activates Panx1 channels and that Panx1 deficiency in cardiomyocytes protects against non-ischemic heart failure and the associated cardiac dysfunction at least in part by reducing immune cell recruitment. Taken together, our study provides evidence for Panx1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in heart failure patients.
cardiac & cardiovascular systems,peripheral vascular disease,hematology